The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...

Please provide your email address to receive an email when new articles are posted on . Nufymco is indicated for the treatment of patients with a number of retinal diseases. The VEGF inhibitor is the ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the ...

AHMEDABAD, India and ZUG, Switzerland, Dec. 23, 2025 /PRNewswire/ -- Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...